WRBL

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
MarketWatch

Intellia Therapeutics Announces Third Quarter -2-

The MarketWatch News Department was not involved in the creation of this content. The company will host a conference call and webcast today at 6:00 p.m. ET to discuss recent updates and the company's ...
Oklahoma's News

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE) Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a ...
WTNH

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Oklahoma's News

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
KRON4 News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
WGHP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA).
FOX31 Denver

Intellia Therapeutics Stock Alert: Intellia Investors with Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - NTLA

PHILADELPHIA, PA / ACCESS Newswire / October 29, 2025 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the ...

Intellia Therapeutics (NTLA) Receives a Buy from Leerink Partners

Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Intellia Therapeutics today and set a price target of $27.00.
WOOD-TV

NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...